The aim of this study was to evaluate the association between Ferredoxin 1 (FDX1) expression and the prognostic survival of tumor patients and predict the efficacy of immunotherapy response to antitumor drug sensitivity. FDX1 plays an oncogenic role in thirty-three types of tumors, based on TCGA and GEO databases, and further experimental validation in vitro was provided through multiple cell lines. FDX1 was expressed highly in multiple types of cancer and differently linked to the survival prognosis of tumorous patients. A high phosphorylation level was correlated with the FDX1 site of S177 in lung cancer. FDX1 exhibited a significant association with infiltrated cancer-associated fibroblasts and CD8+ T cells. Moreover, FDX1 demonstrated correlations with immune and molecular subtypes, as well as functional enrichments in GO/KEGG pathways. Additionally, FDX1 displayed relationships with the tumor mutational burden (TMB), microsatellite instability (MSI), DNA methylation, and RNA and DNA synthesis (RNAss/DNAss) within the tumor microenvironment. Notably, FDX1 exhibited a strong connection with immune checkpoint genes in the co-expression network. The validity of these findings was further confirmed through Western blotting, RT-qPCR, and flow cytometry experiments conducted on WM115 and A375 tumor cells. Elevated FDX1 expression has been linked to the enhanced effectiveness of PD-L1 blockade immunotherapy in melanoma, as observed in the GSE22155 and GSE172320 cohorts. Autodocking simulations have suggested that FDX1 may influence drug resistance by affecting the binding sites of antitumor drugs. Collectively, these findings propose that FDX1 could serve as a novel and valuable biomarker and represent an immunotherapeutic target for augmenting immune responses in various human cancers when used in combination with immune checkpoint inhibitors.
The most frequent internal modification in eukaryotic mRNA is N6-methyladenosine (m6A). However, what we know about the m6A regulators in Ankylosing spondylitis (AS) is still limited. In our study, eight distinct m6A regulators were selected utilizing Differentially Expressed Gene (DEG) analysis of the Gene Expression Omnibus GSE73754 dataset for making comparisons between AS (Ankylosing spondylitis) and non-AS patients. The random forest model and the nomogram model were used to screen the eight candidate m6A regulators and evaluate their prediction accuracy for the occurrence of AS. Furthermore, based on the selected m6A regulators, the AS patients were divided into two subgroups, and we applied principal component analysis algorithms to calculate their m6A score and evaluate the m6A patterns. Our findings revealed that patients in cluster A were linked to activated CD4 T cell immunity and activated CD8 T cell immunity. With its major contributions in the area of immunology, our research in m6A patterns may benefit the future diagnosis and treatment strategies of AS.
Background: RNA 7‐Methylguanosine (m7G) modification is biologically important to tumorigenesis and progression. Knowledge regarding the effect of m7G modification on the clinical features of hepatocellular carcinoma and its prognosis, tumor immune microenvironment, and sensitivity to immunotherapy remains limited.Method: Single‐cell RNA sequencing (scRNA‐seq) data was sourced from the GEO repository. Transcriptomic datasets were procured from TCGA, GEO, and ICGC databases. Following this, we scrutinized 17 m7G‐associated genes and executed unsupervised clustering to discern m7G modification profiles within HCC. Evaluation of immune cell infiltration levels and associated biological functions across varied m7G modification patterns was conducted using single‐sample gene set enrichment analysis (ssGSEA) complemented by gene set variation analysis (GSVA). In addition, we employed principal component analysis methodologies to elucidate m7G modification profiles in individual tumors and subsequently devised the m7Gscore. Data pertaining to m7G‐related protein and mRNA levels were sourced from the Human Protein Atlas (HPA) database. These findings were corroborated in both HCC and normal samples utilizing western blot analysis, immunohistochemical assays, and RT‐qPCR evaluations.Results: Our analysis unveiled diverse cellular subgroups within HCC, with a particular focus on T‐cell populations, providing insights into the intricate interplay of immune activation and suppression within the tumor microenvironment (TME). HCC patients were stratified into three distinct m7G modification patterns: immune‐desert, immune‐inflamed, and immune‐excluded. Subsequently, m7Gscores, derived from m7G‐associated signature genes, categorized HCC patients into high and low m7Gscore groups. Patients in the high‐score cohort exhibited significantly improved survival outcomes compared to those in the low‐score cohort. Elevated m7Gscores also correlated with enhanced therapeutic responsiveness, leading to improved outcomes in both chemotherapy and immunotherapy regimens. Our findings were further validated through RT‐qPCR, western blot analyses, and immunohistochemical assays, providing robust support for our bioinformatic observations.Conclusion: The m7G modification profiles play a pivotal role in prognosticating outcomes for HCC patients, intricately intertwined with microenvironmental heterogeneity and complexity. Furthermore, the analytical insights gained from the m7Gscore signature not only shed light on tumor microenvironment infiltration dynamics but also strengthen prognostic precision, paving the way for optimizing immunotherapeutic approaches in HCC.